Share This Page
LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE Drug Patent Profile
✉ Email this page to a colleague
When do Lamivudine And Tenofovir Disoproxil Fumarate patents expire, and what generic alternatives are available?
Lamivudine And Tenofovir Disoproxil Fumarate is a drug marketed by Aurobindo Pharma Ltd and is included in one NDA.
The generic ingredient in LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE is lamivudine; tenofovir disoproxil fumarate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the lamivudine; tenofovir disoproxil fumarate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE?
- What are the global sales for LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE?
- What is Average Wholesale Price for LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE?
Summary for LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 86 |
| DailyMed Link: | LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE at DailyMed |
Recent Clinical Trials for LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Johns Hopkins University | PHASE3 |
| ViiV Healthcare | PHASE3 |
| Abdelrahman Mahmoud | PHASE2 |
See all LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE clinical trials
US Patents and Regulatory Information for LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aurobindo Pharma Ltd | LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE | lamivudine; tenofovir disoproxil fumarate | TABLET;ORAL | 022344-001 | May 15, 2018 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Lamivudine and Tenofovir Disoproxil Fumarate (TDF) Market Dynamics and Financial Trajectory (2020-2030): Pricing, Share, Exclusivity, and Generic/Biosimilar Risk
Lamivudine + tenofovir disoproxil fumarate (TDF) fixed-dose combinations (FDCs), principally 3TC/TDF marketed as Truvada (Gilead) and generic 3TC/TDF equivalents, sit in a mature HIV market dominated by price erosion, broad formulary coverage, and high generic penetration. From a financial-trajectory standpoint, the commercial base increasingly depends on (1) sustained use in ongoing HIV treatment and prevention, (2) the rate of conversion from originator to lowest-cost generic FDCs, and (3) displacement by newer regimens that reduce reliance on TDF-based backbones.
No biosimilar pathways apply to these small-molecule products. The market risk is dominated by generic entry and price compression, plus therapeutic displacement.
Core market reality
- Major revenue driver: HIV prevention (PrEP) and chronic HIV treatment.
- Primary competitive force: generic 3TC/TDF and multi-drug FDCs that substitute for TDF-based regimens in guidelines and formularies.
- Key financial lever: global purchasing power tied to tenders, national formularies, and donor procurement (for much of the global south).
- Expected trajectory (directionally): originator revenue is in structural decline or stagnation, while generic share expands and margins compress.
What drives demand for lamivudine + tenofovir disoproxil fumarate in HIV treatment and PrEP?
The demand engine for lamivudine/TDF is split between treatment and prevention. The same backbone appears across indications, but the spending model differs.
HIV treatment demand drivers
- Backbone utility: TDF remains a common nucleos(t)ide reverse transcriptase inhibitor backbone in many first-line and switch strategies (with variability by country and patient profile).
- Fixed-dose adherence: the FDC format improves adherence versus multi-pill regimens.
- Cost controls: payers prefer low acquisition cost and predictable supply, favoring generics after originator patent protection and market authorization barriers drop.
PrEP demand drivers
- Population-level uptake: PrEP expansion depends on screening capacity, eligibility rules, and payer willingness to cover prophylaxis.
- Regimen competition: TDF-based PrEP faces substitution risk from alternative PrEP formulations and strategies (including long-acting options in some settings), but in many markets it remains a default due to cost and supply stability.
Commercial implication
Even when clinical guidelines remain permissive for TDF-based regimens, economic access usually determines which exact products win formularies. Generic 3TC/TDF becomes the “default spend” once procurement rules allow.
How do generic entry and patent expiry change pricing and revenue for Truvada-like 3TC/TDF products?
For 3TC/TDF FDCs, the financial trajectory is typically characterized by:
- Originator premium during exclusivity.
- Rapid price deflation once multiple generics enter and contracts are tendered.
- Margin compression for both brand and early entrants as competition becomes lowest-cost based.
Originator vs generic economics
- Originator (Gilead Truvada): higher launch pricing and stronger initial reimbursement, but exposure rises to procurement-driven price cuts over time.
- Generics: after entry, they compete on price, bioequivalence, and supply assurances rather than differentiation.
Practical market dynamic: “winner pricing”
In both the US and ex-US markets, pricing outcomes increasingly track:
- tender outcomes (public procurement),
- formulary position (managed care),
- net price after rebates/discounts,
- competition intensity (number of authorized ANDA/FDA approvals and later distribution channel coverage).
Financial trajectory pattern
- Brand revenue elasticity: brand sales tend to fall faster in categories where payers can switch quickly to generics without clinical management overhead.
- Generic revenue stability: generic volumes often remain steady or grow even as prices decline, provided supply and manufacturing capacity scale.
What is the patent and exclusivity landscape for lamivudine + tenofovir disoproxil fumarate, and when does exclusivity end?
The legal risk profile for lamivudine/TDF is not biosimilar-led; it is generic-led and driven by:
- composition-of-matter patents covering the actives and/or salts,
- method-of-use patents for HIV treatment and/or PrEP,
- formulation/combination patents specific to the FDC.
Why the exclusivity question matters financially
Even when a formulation is broadly used clinically, the originator’s revenue stability depends on whether:
- method-of-use claims remain enforceable against generics attempting label carve-ins, or
- formulation patents delay FDC substitution at the pharmacy benefit manager level.
What typically happens post-exclusivity
- multiple generics enter the market,
- payers accelerate substitution,
- originator net prices decline due to contracting leverage.
What patents protect Truvada (3TC/TDF), and how does the patent estate affect generic entry risk?
From a generic-entry-risk standpoint, the “effective barrier” is rarely a single patent. It is the combined ability to:
- launch without infringing active/use/formulation claims,
- maintain label positions that do not trigger design-around disputes,
- avoid injunction risk during Paragraph IV litigation.
How patent estate strength translates into market timing
- Stronger estate: delays generic conversion in key channels, sustaining originator unit share longer.
- Weaker estate or easy design-arounds: faster generic share gains and faster net price collapse.
Litigation-linked commercialization
In mature small-molecule HIV combinations, litigation often ends with settlements that set:
- delayed launch dates,
- shared-risk designations,
- permitted launch triggers tied to patent cliffs.
Those settlement structures determine the pace of market share transfer from originator to generic.
What generic entry risks exist for lamivudine + tenofovir disoproxil fumarate in the US (ANDA and Paragraph IV)?
Generic entry is usually channelized through ANDAs and Paragraph IV certifications against Orange Book-listed patents (where applicable). The core business impacts are:
- timing of first generic FDC availability at scale
- rate of adoption by payers
- sequencing of competitors (first wave vs subsequent approvals)
Commercial mechanism
Once a first wave generic gains meaningful payer adoption, it forces price adjustments across the category. Later entrants typically reduce prices further unless they secure differentiated procurement lanes (which is less common for undifferentiated FDCs).
What is the Orange Book status of lamivudine + tenofovir disoproxil fumarate products?
Orange Book status determines which patents are tied to:
- the approved NDA,
- the exact FDC strengths and dosage forms,
- listed method-of-use claims.
Orange Book listings also define the certification landscape for ANDAs and the likelihood of Paragraph IV litigation.
Business read-through
- A dense Orange Book listing typically increases the probability of litigation and settlement delay.
- A sparse listing increases the probability of faster generic conversion.
How does lamivudine/TDF (3TC/TDF) compare with newer HIV regimens that displace TDF-based backbones?
Substitution risk is a major financial variable because it can reduce the total addressable market for TDF-based backbones.
Direct comparison axes that matter commercially
- clinical guideline inclusion (first-line and switch recommendations),
- renal and bone safety profiles that influence selection,
- pill burden and tolerability affecting adherence and regimen choice,
- market availability and price of alternatives (including TAF-based or integrase-heavy regimens).
Typical displacement pattern
Even when TDF stays in use, competitors can:
- reduce share in initiation populations,
- increase share in “switch away from TDF” populations,
- win prevention conversions where alternatives are covered.
How strong is the patent estate for lamivudine + tenofovir disoproxil fumarate versus competing HIV backbones (TAF-based and INSTI-based FDCs)?
Patent strength is best viewed through relative time-to-next-generic constraints in the relevant markets.
Competitive shift risk
- If TAF-based or INSTI-based FDCs hold stronger exclusivity, payers can reallocate spend away from TDF combinations earlier.
- If TDF generics are already broadly available, the main remaining constraint is clinical switching inertia rather than legal exclusivity.
Financial consequence
- If displacement accelerates: volumes decline even if pricing holds.
- If only pricing collapses but volumes hold: revenue declines via margin compression.
What formulation and manufacturing/IP barriers affect availability of lamivudine/TDF generics?
For small-molecule FDCs, the barriers are typically:
- bioequivalence and formulation consistency across strengths,
- scale-up and quality systems at contract manufacturers,
- control of sourcing and active pharmaceutical ingredient (API) supply chains.
Market impact
Manufacturing reliability can determine which generic entrants can sustain pharmacy supply and keep contracts. Temporary shortages can protect price temporarily, but this is usually not a long-term structural advantage.
What financial trajectory does the lamivudine/TDF market show by channel: US insured, Medicaid, and ex-US public procurement?
Commercial trajectory varies by reimbursement infrastructure.
US channel
- Managed care formulary management drives switching to the lowest net-cost generic.
- Net pricing, rebates, and contracting outcomes can smooth or accelerate decline.
Medicaid and public systems
- State-level procurement often favors the lowest-priced or best-value products.
- Once multiple generics are available, conversion can happen quickly through pharmacy benefit switches.
Ex-US
- Tendencies lean toward competitive tendering.
- Donor procurement and national program buying can shift volumes rapidly to the least-cost supplier meeting specifications.
How do pricing dynamics typically evolve after generic substitution in 3TC/TDF markets?
Post-substitution patterns in mature generics categories usually show:
- steep initial price drops when first generics are adopted,
- further compression as more competitors enter and contracts reset,
- stabilization at a lower floor tied to API input costs and manufacturing economics.
Key cost variables
- API commodity cycles for tenofovir and lamivudine,
- manufacturing capacity utilization and quality compliance costs,
- logistics and country-specific regulatory filing burdens.
What impact does contract manufacturing capacity and API supply volatility have on revenue for lamivudine/TDF suppliers?
Even in an IP-rich category, supply constraints can dominate short-term revenue.
Revenue levers
- A supplier with reliable supply can keep contracts despite competitors’ disruptions.
- A supplier with constrained capacity faces lost orders that may be reallocated permanently.
Practical market outcome
- In high-uptake programs (especially PrEP scale-up markets), supply continuity can protect volume and reduce switching to alternative products.
What does the competitive landscape look like for lamivudine + tenofovir disoproxil fumarate across major geographies?
Competitive structure
- Originator: typically one brand product with strong clinical familiarity.
- Generics: multiple authorized suppliers depending on geography and approvals.
- Alternative backbones: competing FDCs that can reduce TDF-based share even if 3TC/TDF remains available.
Commercial implication
The competitive fight is less about “science differentiation” and more about:
- lowest net price,
- procurement responsiveness,
- supply reliability,
- contract renewals.
What key metrics should be used to track lamivudine/TDF financial performance over time?
Financial KPI set (actionable)
- US and ex-US unit volume by dosage strength (where available).
- Average unit net price post-generic entry.
- Formulary coverage (number of covered plans and tiers).
- Tender participation and won contracts for public procurement.
- Share of prescriptions moving between 3TC/TDF and competing backbones.
Legal KPI set
- Status of Orange Book-listed patents for the specific NDA and strengths.
- Presence of ANDA Paragraph IV litigation and settlement-triggered launch dates.
Key Takeaways
- Lamivudine/TDF (3TC/TDF) demand remains structurally supported by HIV treatment and PrEP, but the financial upside is capped by mature generic competition and price compression.
- Originator brand revenue trajectory is primarily driven by generic substitution speed and net price erosion, not by biosimilar risk (none applies).
- The largest additional headwind is therapeutic displacement away from TDF-based backbones into newer regimens, which can reduce addressable volumes even when generics are available.
- The most predictive monitoring metrics are unit volumes, net pricing, formulary coverage, and procurement tender outcomes, alongside Orange Book-linked patent status that governs launch timing for additional ANDA waves.
FAQs
1) Do lamivudine + tenofovir disoproxil fumarate products have biosimilar competition?
No. They are small molecules. Competitive entry is via generic ANDAs, not biosimilars.
2) Which tends to impact revenue more for Truvada-like 3TC/TDF products: generic price erosion or regimen displacement?
Both matter, but price erosion typically dominates near-term revenue as substitution accelerates; regimen displacement becomes more important when initiation and switch patterns shift.
3) How do settlement agreements influence the timing of generic launches for 3TC/TDF?
They often set launch dates or trigger terms tied to patent cliffs, shaping how quickly payer coverage converts to the lowest-cost generic.
4) Are method-of-use patents a meaningful barrier for generic lamivudine/TDF in HIV PrEP?
They can be. If method-of-use claims remain enforceable, generic label constraints and litigation can delay practical uptake in certain channels.
5) What procurement levers most quickly accelerate generic substitution of 3TC/TDF?
Formulary tiering, rebate contracting terms, and public procurement tender awards that reset purchasing around lowest net cost after generic availability.
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. Drug Approval Reports and related regulatory information for Truvada and related products. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases
- Centers for Disease Control and Prevention. Pre-exposure prophylaxis (PrEP) guidance and related HIV prevention resources. CDC. https://www.cdc.gov/hiv/prevention/
More… ↓
